viking-therapeutics

This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Viking Therapeutics reported clinical-trial results showing its investigational GLP-1/GIP candidate VK2735 helped participants maintain prior weight loss, including when dosed once monthly. The company’s shares climbed sharply on the news as VK2735 is positioned as a potential rival to Eli Lilly’s Zepbound.